VIA
NGM

Vident Investment Advisory’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Vident Investment Advisory’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-48,046
Closed -$628K – 1364
2022
Q3 		$628K Sell
48,046
-5,148
-10% -$78K 0.02% 719
2022
Q2 		$682K Buy
+53,194
New +$737K 0.02% 757

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vident Investment Advisory's NGM Position: Q4 2022 in Review

Vident Investment Advisory sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 48,046 shares — an estimated $628K sold.

Vident Investment Advisory first reported a position in NGM in Q2 2022 and held it in 2 quarters. The position peaked at $682K in Q2 2022. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Vident Investment Advisory reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 48,046 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $628K.
  • Vident Investment Advisory first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Vident Investment Advisory's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $682K in Q2 2022.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.